|
|
Vir Biotechnology Inc (VIR) |
|
Price: $9.3500
$0.21 
2.298%
|
| Day's High:
| $9.515
| Week Perf:
| -2.91 %
|
| Day's Low: |
$ 8.90 |
30 Day Perf: |
-27.91 % |
| Volume (M): |
2,258 |
52 Wk High: |
$ 31.55 |
| Volume (M$): |
$ 21,113 |
52 Wk Avg: |
$22.53 |
| Open: |
$9.16 |
52 Wk Low: |
$8.90 |
|
|
| Market Capitalization (Millions $) |
1,253 |
| Shares
Outstanding (Millions) |
134 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
491 |
| Net Income (TTM) (Millions $) |
-262 |
| Cash Flow (TTM) (Millions $) |
-840 |
| Capital Exp. (TTM) (Millions $) |
48 |
Vir Biotechnology Inc
Vir Biotechnology Inc is a clinical-stage immunology company focused on developing therapies to treat infectious diseases.
The company was founded in 2016 by George Scangos, a former CEO of Biogen.
The company has its headquarters in San Francisco, California and operates in the United States and the United Kingdom.
Vir is focused on developing treatments for viral infections such as hepatitis B virus, respiratory syncytial virus (RSV), influenza, and novel coronaviruses like SARS-CoV-2.
The company is looking to leverage its expertise in immunology and virology to develop novel treatments that can improve patient outcomes and reduce the spread of infectious diseases.
Vir has a diverse pipeline of product candidates, including monoclonal antibodies, antivirals, and vaccines, that are being developed for a range of viral infections.
The company has several partnerships and collaborations with leading pharmaceutical companies, including GlaxoSmithKline, Biogen, and Alnylam.
Vir has a strong management team and scientific advisory board, comprising experts in virology, immunology, and drug development.
The company has raised over $2 billion in funding to support its research and development efforts.
Overall, Vir Biotechnology Inc is a promising biotech company with a focus on developing innovative treatments for infectious diseases.
With a strong pipeline of product candidates and partnerships with established pharmaceutical companies, the company is well-positioned to make a significant impact in the fight against viral infections.
Company Address: 499 Illinois Street San Francisco 94158 CA
Company Phone Number: 906-4324 Stock Exchange / Ticker: NASDAQ VIR
| VIR is expected to report next financial results on November 02, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Pharmacyte Biotech Inc
Pharmacyte Biotech Inc: Analyzing Changes in Company Performance
The stockholders of Pharmacyte Biotech Inc were taken by surprise during the May to July 31, 2023 reporting cycle, as unforeseen changes occurred within the business. These changes were primarily reflected in the company's operating loss, which amounted to $-2.075326 million during the aforementioned period. For investors, monitoring this operating loss was crucial in assessing the company's performance.
To better understand the recent fiscal period results, it is important to analyze the preceding quarter. The operating loss in the first quarter of 2023 was $-1.680608 million, indicating a slight improvement compared to the subsequent period. It is worth noting that businesses often experience fluctuating performance, especially when trying to stimulate lucrative revenue streams. The May to July 31, 2023 period was one such instance where shortfalls extended to $-3.183 million.
|
|
Organicell Regenerative Medicine Inc
Organicell Regenerative Medicine Inc Reaches Break-Even in Q3 2023
During the third quarter of 2023, Organicell Regenerative Medicine Inc reached a break-even point of $0.00 per share, compared to the same period last year and the preceding reporting period. This achievement indicates the company's ability to generate revenue to cover its expenses.
However, the company experienced a significant decline in revenue, which crumbled by -28.749% to $1.22 million from $1.71 million during the comparable reporting period a year ago. On the positive side, there was a sequential revenue surge of 44.373% from $0.85 million. This indicates that, while the year-over-year comparison may seem negative, the company has seen substantial growth compared to the previous quarter.
Organicell Regenerative Medicine Inc reported a net shortfall of $-1.618 million in the third quarter of 2023, which is an improvement from a deficit of $-2.727 million in the same reporting period a year ago. This reduction in the net shortfall indicates that the company has managed to control its expenses better, leading to a smaller financial deficit.
|
|
Champions Oncology Inc
Champions Oncology Inc, a company listed on the NASDAQ, has experienced some fluctuations in its stock performance recently. In the preceding month, the stock declined by -3.59%, indicating a slight decrease in investor confidence. However, when considering the overall trend, the stock is still showing a significant increase of 52.04% in 2023.
Currently, Champions Oncology Inc's stock is trading on the NASDAQ at a level that is 15.3% above its 52-week average. This suggests that investors have generally been optimistic about the company's prospects, as the stock is trading at a higher price than what has been seen over the past year.
However, the company's financial performance in the first quarter of 2024 has been less than desirable. Lower turnover has resulted in dwindling revenue, which has further exacerbated an increased shortfall. The company experienced a net shortfall of $-0.19 per share, a significant decline compared to the previous reporting period where the bottom line was also $-0.19 per share.
|
|
Pluri Inc
Pluri Inc, a biotechnology and pharmaceutical company, has recently witnessed a decline in its shares and reported disappointing financial results for the fiscal year closing June 30, 2023. This article will analyze the implications of these results and examine the potential impact on the company in the future.
Decreasing Share Performance:
Over the past week, Pluri Inc's shares experienced a decline of -6.25%, reaching their 52-week low. When considering the year to date performance, the shares have suffered a significant decrease of -41.16%. These figures signal a bearish sentiment among investors and raise concerns about the future prospects of the company.
|
|
Mesoblast Ltd
Mesoblast Ltd, a biotechnology and pharmaceutical company, has recently released its financial results for the most recent fiscal period. The company reported a decline in demand, which resulted in an increase in shortfall per share from $-0.14 to $-0.11. Additionally, revenue dropped by a significant -26.56% from $10.21 million to $7.50 million compared to the previous year.
In comparison to the previous quarter, Mesoblast Ltd's revenue for the current fiscal period remained low at $7.50 million, with no significant improvement. However, it is worth noting that the company's net shortfall of $-81.889 million in April to June 2023 fiscal timeframe showed a slight improvement from a deficit of $-91.347 million in the same quarter a year ago.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.94 $ |
| Revenues (TTM) |
3.66 $
|
| Cash Flow (TTM) |
- |
| Cash |
13.78 $
|
| Book Value |
13.5 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.94 $
|
| Revenues (TTM) |
3.66 $ |
| Cash Flow (TTM) |
- |
| Cash |
13.78 $
|
| Book Value |
13.5 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
